Pharmaceutical

Mission Therapeutics forges ahead with Phase II study for DUB inhibitor 

A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.

Dec 14, 2023 - 18:00
Mission Therapeutics forges ahead with Phase II study for DUB inhibitor 
A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.
Read the original article

Tags:

Previous Article

Novo Nordisk acquires Alkermes’s Irish plant to expand manufacturing capacity

Next Article

Eight evolving patient communication risks in pharma and biotech

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Prevention over cure? Understanding the evolved care continuum and centralised data

Prevention over cure? Understanding the evolved care co...

Mar 20, 2024

STAT+: Health insurance CEOs set another record for pay in 2022

STAT+: Health insurance CEOs set another record for pay...

Apr 27, 2023

Opinion: Health misinformation is rampant in youth baseball. Why isn’t MLB doing more to help?

Opinion: Health misinformation is rampant in youth base...

Jun 26, 2023